Evidence map›Paper›PMID 36722044›Full record

Trial reportThe Journal of infectious diseases2023

Symptom Duration and Resolution With Early Outpatient Treatment of Convalescent Plasma for Coronavirus Disease 2019: A Randomized Trial.

Sheriza N Baksh, Sonya L Heath, Yuriko Fukuta, David Shade, Barry Meisenberg, Evan M Bloch, Aaron A R Tobian, Emily S Spivak, Bela Patel, Jonathan Gerber and 16 more

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04373460 (Comparison of the Efficacy and Safety of Human Coronavirus Immune Plasma), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04373460 phase2completednot on this map

Comparison of the Efficacy and Safety of Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune) Plasma Among Outpatients With Symptomatic COVID-19

TypeinterventionalSponsorJohns Hopkins UniversityRan2020 to 2022Enrolled1,225ConditionsSARS-CoV 2ArmsSARS-CoV-2 convalescent plasma, Plasma from a volunteer donor
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Sheriza N BakshDepartment of Epidemiology Bloomberg Johns Hopkins School of Public Health, Baltimore, Maryland, USA.ORCID 0000-0002-8341-860X
Sonya L HeathDepartment of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Yuriko FukutaDepartment of Medicine, Section of Infectious Diseases, Baylor College of Medicine, Houston, Texas, USA.
David ShadeDepartment of Epidemiology Bloomberg Johns Hopkins School of Public Health, Baltimore, Maryland, USA.
Barry MeisenbergDepartment of Medicine and Research Institute of Luminis Health, Annapolis, Maryland, USA.
Evan M BlochDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Aaron A R TobianDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Emily S SpivakDepartment of Medicine, Division of Infectious Diseases, University of Utah, Salt Lake City, Utah, USA.
Bela PatelDepartment of Medicine, Divisions of Pulmonary and Critical Care Medicine, University of Texas Health Science Center, Houston, Texas, USA.
Jonathan GerberDepartment of Medicine, Division of Hematology and Oncology, University of Massachusetts, Worchester, Massachusetts, USA.
Jay S RavalDepartment of Pathology, University of New Mexico, Albuquerque, New Mexico, USA.
Donald ForthalDepartment of Medicine, Division of Infectious Diseases, University of California, Irvine, Irvine, California, USA.
James PaxtonDepartment of Emergency Medicine, Wayne State University, Detroit, Michigan, USA.
Giselle MosnaimDepartment of Medicine Northshore University Health System, Division of Allergy and Immunology, Evanston, Illinois, USA.
Shweta AnjanDepartment of Medicine, Division of Infectious Diseases, University of Miami, Miami, Florida, USA.ORCID 0000-0002-7761-1163
Janis BlairDepartment of Medicine, Division of Infectious Diseases, Mayo Clinic, Phoenix, Phoenix, Arizona, USA.
Edward CachayDepartment of Medicine, Division of Infectious Diseases, University of California, San Diego, La Jolla, California, USA.
Judith CurrierDepartment of Medicine, Division of Infectious Diseases, University of California, Los Angeles, Los Angeles, California, USA.ORCID 0000-0003-4279-4737
Piyali DasDepartment of Neurology, Brain Injury Outcomes Division, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Moises HuamanDepartment of Medicine, Division of Infectious Diseases, University of Cincinnati Medical Center, Cincinnati, Ohio, USA.
Catherine SutcliffeDepartment of Epidemiology Bloomberg Johns Hopkins School of Public Health, Baltimore, Maryland, USA.
Anusha YaravaDepartment of Neurology, Brain Injury Outcomes Division, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Arturo CasadevallDepartments of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.ORCID 0000-0002-9402-9167
David SullivanDepartments of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Daniel HanleyDepartment of Neurology, Brain Injury Outcomes Division, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Kelly A GeboDepartment of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Funding

Johns Hopkins-Tufts Trial Innovation Center HEAL Pain ERN SupplementU24TR001609 · NCATS · JOHNS HOPKINS UNIVERSITY · PI HANLEY, DANIEL F · 2016 to 2022
$36.3M
CTSA UM1 Program at University of UtahUM1TR004409 · NCATS · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI RACHEL HESS, Jennifer Juhl Majersik · 2023 to 2026
$21.9M
The Malaria Transfusion Risk (MATRix) StudyK23HL151826 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI BLOCH, EVAN MARTIN · 2020 to 2024
$882k
NCATS NIH HHS U24 TR001609NCATS NIH HHS UM1 TR004409NHLBI NIH HHS K23 HL151826
6 · The paper itself

Abstract

backgroundCoronavirus disease 2019 (COVID-19) convalescent plasma (CCP) reduces hospitalizations among outpatients treated early after symptom onset. It is unknown whether CCP reduces time to symptom resolution among outpatients.

methodsWe evaluated symptom resolution at day 14 by trial arm using an adjusted subdistribution hazard model, with hospitalization as a competing risk. We also assessed the prevalence of symptom clusters at day 14 between treatments. Clusters were defined based on biologic clustering, impact on ability to work, and an algorithm.

resultsAmong 1070 outpatients followed up after transfusion, 381 of 538 (70.8%) receiving CCP and 381 of 532 (71.6%) receiving control plasma were still symptomatic (P = .78) at day 14. Associations between CCP and symptom resolution by day 14 did not differ significantly from those in controls after adjustment for baseline characteristics (adjusted subdistribution hazard ratio, 0.99; P = .62). The most common cluster consisted of cough, fatigue, shortness of breath, and headache and was found in 308 (57.2%) and 325 (61.1%) of CCP and control plasma recipients, respectively (P = .16).

conclusionsIn this trial of outpatients with early COVID-19, CCP was not associated with faster resolution of symptoms compared with control. Overall, there were no differences by treatment in the prevalence of each symptom or symptom clusters at day 14. CLINICAL TRIALS REGISTRATION: NCT04373460.

Indexed as

COVID-19COVID-19 SerotherapyHumansImmunization, PassiveOutpatientsSARS-CoV-2SyndromeCOVID-19COVID-19 serotherapyplasmasymptom duration

Identifiers

PMID36722044
PMCPMC10226658

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.